Article in mSystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Charlie BayneBiomedical Sciences Graduate Program, UC San Diego, La Jolla, San Diego, California, USA.ORCID 0000-0003-1870-5298
Dominic McGrossoBiomedical Sciences Graduate Program, UC San Diego, La Jolla, San Diego, California, USA.
Concepcion SanchezBiomedical Sciences Graduate Program, UC San Diego, La Jolla, San Diego, California, USA.
Leigh-Ana RossittoBiomedical Sciences Graduate Program, UC San Diego, La Jolla, San Diego, California, USA.ORCID 0000-0002-7744-3630
Maxwell PattersonDepartment of Pharmacology, University of California San Diego, La Jolla, San Diego, California, USA.
Carlos GonzalezDepartment of Pharmacology, University of California San Diego, La Jolla, San Diego, California, USA.ORCID 0000-0002-4673-4048
Courtney BausDepartment of Pharmacy, UW Health, Madison, Wisconsin, USA.
Cecilia VolkSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Haoqi Nina ZhaoSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego, California, USA.ORCID 0000-0003-3908-630X
Pieter DorresteinDepartment of Pharmacology, University of California San Diego, La Jolla, San Diego, California, USA.
Victor NizetDepartment of Pharmacology, University of California San Diego, La Jolla, San Diego, California, USA.ORCID 0000-0003-3847-0422
George SakoulasDepartment of Pediatrics, UC San Diego, La Jolla, San Diego, California, USA.ORCID 0000-0002-6063-6217
David J GonzalezDepartment of Pharmacology, University of California San Diego, La Jolla, San Diego, California, USA.ORCID 0000-0003-1423-5970
Warren RoseSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-5012-5993
Funding
UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Rheumatic Diseases Research Training GrantT32AR064194 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARY S FIRESTEIN, Monica Guma · 2013 to 2026
$3.8M
Contribution of the peptidome to CA-MRSA virulenceR01AI148417 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GONZALEZ, DAVID J · 2020 to 2024
$2.0M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI148417HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) AR064194HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM007752NIAID NIH HHS R01 AI148417NIAMS NIH HHS T32 AR064194NIGMS NIH HHS K12 GM068524NIGMS NIH HHS T32 GM007752
6 · The paper itself
Abstract
Despite the prevalence and severity of enterococcal bacteremia (EcB), the mechanisms underlying systemic host responses to the disease remain unclear. Here, we present an extensive study that profiles molecular differences in plasma from EcB patients using an unbiased multi-omics approach. We performed shotgun proteomics and metabolomics on 105 plasma samples, including those from EcB patients and healthy volunteers. Comparison between healthy volunteer and EcB-infected patient samples revealed significant disparities in proteins and metabolites involved in the acute phase response, inflammatory processes, and cholestasis. Several features distinguish these two groups with remarkable accuracy. Cross-referencing EcB signatures with those of IMPORTANCE:
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Multi-omic signatures of host response associated with presence, type, and outcome of enterococcal bacteremia. · full record | OpenQuestion